Symbiotec Zenfold Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 135.00 Cr
as on 19-12-2024
- Revenue %
(FY 2023)
- Profit 72.65%
(FY 2023)
- Ebitda -7325.80%
(FY 2023)
- Net Worth -22.96%
(FY 2023)
- Total Assets 324.76%
(FY 2023)
About Symbiotec Zenfold
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹135.00 Cr.
Anil Satwani, Buggana Hariharnath, and Rohit Mantri serve as directors at the Company.
- CIN/LLPIN
U24100MP2020PTC052495
- Company No.
052495
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Aug 2020
- Date of AGM
26 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Symbiotec Zenfold?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohit Mantri  | Nominee Director | 26-Aug-2020 | Current |
| Anil Satwani | Director | 26-Aug-2020 | Current |
Buggana Hariharnath  | Nominee Director | 16-Sep-2024 | Current |
Financial Performance and Corporate Structure Insights of Symbiotec Zenfold.
Symbiotec Lifesciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 72.65% increase in profit. The company's net worth observed a substantial decline by a decrease of 22.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symbiotec Zenfold?
In 2023, Symbiotec Zenfold had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Symbiotec Pharmalab Private LimitedActive 22 years 3 monthsAnil Satwani and Rohit Mantri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 29 Aug 2022 | ₹135.00 Cr | Open |
How Many Employees Work at Symbiotec Zenfold?
Unlock and access historical data on people associated with Symbiotec Zenfold, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symbiotec Zenfold, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symbiotec Zenfold's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
